Table 1.
Characteristics of Patients Recruited Into the Study
| UST (n = 23) | TNF (n = 21) | HD (n = 22) | P Value | |
|---|---|---|---|---|
| Patients included in longitudinal analysis | 17 | — | — | — |
| Age, y | 35.1 ± 10.7 | 35.38 ± 9.0 | 34.8 ± 10.9 | — |
| Female | 16 (70) | 15 (71) | 15 (68) | — |
| HBI | 6.7 ± 9.1 | 4 ± 3.9 | — | .4 |
| C-reactive protein, mg/L | 23 ± 38 | 26 ± 77 | — | .14 |
| Leukocytes, ×103/μL | 8.9 ± 2.3 | 9.3 ± 4.1 | — | .9 |
| Current therapy with prednisone | 2 (9) | 0 (0) | — | — |
| Current therapy with budesonide | 1 (4) | 1 (5) | — | — |
| Previous therapy with azathioprine | 18 (76) | 16 (76) | — | — |
| Previous therapy with MTX | 7 (30) | 2 (10) | — | — |
| Previous therapy with 6-mercaptopurine | 2 (9) | 1 (5) | — | — |
| Previous therapy with mesalamine | 12 (52) | 4 (19) | — | — |
| Previous therapy with 1 anti-TNF-AB | 9 (39) | 5 (24) | — | — |
| Previous therapy with 2 anti-TNF-AB | 12 (52) | 0 (0) | — | — |
| Previous therapy with 3 anti TNF-AB | 2 (9) | 0 (0) | — | — |
| Previous therapy with vedolizumab | 4 (17) | 1(5) | — | — |
| Stricturing disease | 13 (57) | 11 (58) | — | — |
| Penetrating disease | 10 (43) | 8 (41) | — | — |
| Previous CD-related surgery | 15 (65) | 11 (58) | — | — |
| Clinical responders | 14 (61) | 10 (48) | — | — |
Values are mean ± SD or n (%). Markers of disease activity and inflammation between UST and anti-TNF–treated patients were analyzed by Mann-Whitney test.
AB, antibody; CD, Crohn’s disease; HBI, Harvey-Bradshaw Index; HD, healthy donor; MTX, methotrexate; TNF, tumor necrosis factor; UST, ustekinumab.